Hypoxia-directed drug strategies to target the tumor microenvironment

Advances in Experimental Medicine and Biology

Volumn 772, Issue , 2014, Pages 111-145

  Hay, Michael P ^a   Hicks, Kevin O ^a   Wang, Jingli ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Biomarker; Drug discovery; Glucose transport; HIF 1 ; Hypoxia; Hypoxia activated prodrug; Nitroimidazole; Radiosensitizer; SN30000; Tirapazamine

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYTOTOXIN; DORANIDAZOLE; DOXORUBICIN; GEMCITABINE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMORAZOLE; NITROIMIDAZOLE; P 104; PR 104; RADIOSENSITIZING AGENT; SN 30000; TIRAPAZAMINE; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL KILLING; CHEMORADIOTHERAPY; CONFERENCE PAPER; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLIOMA; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NONHUMAN; OXYGEN TENSION; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; STEREOTACTIC BODY RADIATION THERAPY; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA REPAIR; DRUG DISCOVERY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR MICROENVIRONMENT;

EID: 84934436583     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5915-6_6     Document Type: Conference Paper

References (287)

1. Adams PC, Rickert DE (1995) Metabolism of [C-14]1, 3-dinitrobenzene by rat small intestinal mucosa in vitro. Drug Metab Dispos 23:982-987
2. Adams GE, Dische S, Fowler JF et al (1976) Hypoxic cell sensitisers in radiotherapy. Lancet 1:186-188
3. Adams GE, Clarke ED, Flockhart IR et al (1979a) Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med 35:133-150
4. Adams GE, Clarke ED, Gray P et al (1979b) Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol Relat Stud Phys Chem Med 35:151-160
5. Aghajanian C, Brown C, O'flaherty C et al (1997) Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 67:127-130
6. Albert JM, Cao C, Kim KW et al (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13:3033-3042
7. Anderson RF, Shinde SS, Hay MP et al (2003) Activation of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125:748-756
8. Ang KK (2010) More lessons learned from the suffocation of hypoxia. J Clin Oncol 28:2941-2943
9. Ask K, Dijols S, Giroud C et al (2003) Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. Chem Res Toxicol 16:1547-1554
10. Asquith JC, Foster JL, Willson RL et al (1974) Metronidazole ("Flagyl"). A radiosensitizer of hypoxic cells. Br J Radiol 47:474-481
11. Baker MA, Zeman EM, Hirst VK et al (1988) Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 48:5947-5952
12. Basu S (2010) Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol 7:665-668
13. Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11:239-253
14. Benito J, Shi Y, Szymanska B et al (2011) Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 6:e23108
15. Bennett MH, Feldmeier J, Smee R et al (2012) Hyperbaric oxygenation for tumor sensitisation to radiotherapy. Cochrane Database Syst Rev 4, CD005007. doi: 10.1002/14651858.CD005007.pub3
16. Berra E, Pages G, Pouyssegur J (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19:139-145
17. Bindra RS, Crosby ME, Glazer PM (2007) Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26:249-260
18. Blunt T, Finnie NJ, Taccioli GE et al (1995) Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 80:813-823
19. Bonnet M, Flanagan JU, Chan DA et al (2011) SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells. Bioorg Med Chem 19:3347-3356
20. Bonnet M, Hay MP, Hicks KO et al (2012) Nitroimidazole compounds and their use in cancer therapy. New Zealand Patent
21. Borad MJ, Reddy R, Bahary N et al (2012) TH-302 plus gemcitabine vs. gemcitabine in patients with untreated advanced pancreatic adenocarcinoma. In: 37th European Society for Medical Oncology (ESMO) 2012 Congress, Vienna, 28 Sep-2 Oct 2012
22. Borch RF, Liu J, Schmidt JP et al (2000) Synthesis and evaluation of nitroheterocyclic phos-phoramidates as hypoxia-selective alkylating agents. J Med Chem 43:2258-2265
23. Borch RF, Liu J, Joswig C et al (2001) Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. J Med Chem 44:74-77
24. Breider MA, Ulloa HM, Pegg DG et al (1998) Nitro-Imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol Pathol 26:651-656
25. Brockmann K, Wang D, Korenke CG et al (2001) Autosomal dominant glut-1 deficiency syndrome and familial epilepsy. Ann Neurol 50:476-485
26. Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumors, and a possible mechanism of reoxygenation. Br J Radiol 52:650-656
27. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 67:1163-1170
28. Brown M (2010) Henry S. Kaplan Distinguished Scientist Award Lecture 2007. The remarkable yin and yang of tumor hypoxia. Int J Radiat Biol 86:907-917
29. Brown JM, Lemmon MJ (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745-7749
30. Brown JM, Lemmon MJ (1991) Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20:457-461
31. Brown JM, Wilson WR (2004) Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4:437-447
32. Brown JM, Goffinet DR, Cleaver JE et al (1971) Preferential radiosensitization of mouse sarcoma relative to normal skin by chronic intra-arterial infusion of halogenated pyrimidine analogs. J Natl Cancer Inst 47:75-89
33. Brown JM, Yu NY, Brown DM et al (1981) SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 7:695-703
34. Brown JM, Diehn M, Loo BW (2010) Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 78:323-327
35. Buffa FM, Harris AL, West CM et al (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102:428-435
36. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95
37. Calabrese CR, Almassy R, Barton S et al (2004) Anticancer chemosensitization and radiosensiti-zation by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96:56-67
38. Camphausen K, Tofilon PJ (2007) Inhibition of histone deacetylation: a strategy for tumor radio-sensitization. J Clin Oncol 25:4051-4056
39. Cao X, Fang L, Gibbs S et al (2007) Glucose uptake inhibitor sensitizes cancer cells to daunorubi-cin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495-505
40. Carlson DJ, Keall PJ, Loo BW Jr et al (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79:1188-1195
41. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264-6270
42. Cazares-Korner C, Pires IM, Swallow ID et al (2013) CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A ACS. Med Chem Letts 8:1451-1459
43. Cenas N, Prast S, Nivinskas H et al (2006) Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem 281:5593-5603
44. Chalmers AJ, Lakshman M, Chan N et al (2010) Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 20:274-281
45. Chan DA, Giaccia AJ (2008) Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle 7:2987-2990
46. Chan DA, Sutphin PD, Nguyen P et al (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3:94ra70
47. Chandor A, Dijols S, Ramassamy B et al (2008) Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by NO synthases. Chem Res Toxicol 21:836-843
48. Chang Q, Jurisica I, Do T et al (2011) Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 71:3110-3120
49. Charrier JD, Durrant SJ, Golec JM et al (2011) Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 54:2320-2330
50. Chawla SP, Ganjoo KN, Adkins D et al (2011) A phase 2 study of TH-302 in combination with doxorubicin in advanced soft tissue sarcoma. In: Connective Tissue Oncology Society (CTOS) annual meeting, Chicago, 26-29 Oct 2011
51. Chen Y, Hu L (2009) Design of anticancer prodrugs for reductive activation. Med Res Rev 29:29-64
52. Chi JT, Wang Z, Nuyten DS et al (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3:e47
53. Chinje EC, Cowen RL, Feng J et al (2003) Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63:1248-1255
54. Chowdhury G, Junnotula V, Daniels JS et al (2007) DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2). J Am Chem Soc 129:12870-12877
55. Cole S, Stratford IJ, Fielden EM et al (1992) Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908. Int J Radiat Oncol Biol Phys 22:545-548
56. Coleman CN, Wasserman TH, Urtasun RC et al (1990) Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) radiation therapy oncology group 83-03. Int J Radiat Oncol Biol Phys 18:389-393
57. Covens A, Blessing J, Bender D et al (2006) A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:586-590
58. Cowan DS, Hicks KO, Wilson WR (1996) Multicellular membranes as an in vitro model for extra-vascular diffusion in tumors. Br J Cancer Suppl 27:S28-S31
59. Craighead PS, Pearcey R, Stuart G (2000) A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 48:791-795
60. Daniels JS, Gates KS (1996) DNA cleavage by the antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J Am Chem Soc 118:3380-3385
61. Denny WA (2010) Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol 6:419-428
62. Denny WA, Wilson WR (1986) Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 29:879-887
63. Denny WA, Wilson WR (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev 12:135-151
64. Denny WA, Wilson WR (2000) Tirapazamine: a bioreductive anticancer drug that exploits tumor hypoxia. Expert Opin Investig Drugs 9:2889-2901
65. Denny WA, Wilson WR, Hay MP (1996) Recent developments in the design of bioreductive drugs. Br J Cancer 74(Suppl XXVII):S32-S38
66. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437
67. Dimmer KS, Friedrich B, Lang F et al (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 350(Pt 1):219-227
68. Dische S (1985) Chemical sensitisers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol 3:97-115
69. Dische S (1991) A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 20:147-152
70. DiSilvestro P, Ali S, Peter C et al (2012) A Gynecologic Oncology Group phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIIB and I VA cervical carcinoma limited to the pelvis. Gynecol Oncol 125(Suppl 1):S3
71. Dorie MJ, Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapaza-mine (SR 4233) and cisplatin. Cancer Res 53:4633-4636
72. Dorie MJ, Brown JM (1994) Potentiation of the anticancer effect of cisplatin by the hypoxic cyto-toxin tirapazamine. In: Vaupel PW, Kelleher DK, Gunderoth M (eds) Tumor oxygenation. Fischer-Verlag, Stuttgart/New York, pp 125-135
73. Duan JX, Jiao H, Kaizerman J et al (2008) Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51:2412-2420
74. Dubois LJ, Lieuwes NG, Janssen MH et al (2011) Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci USA 108:14620-14625
75. Durand RE, Olive PL (1992) Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 22:689-692
76. Durand RE, Olive PL (1997) Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5:213-219
77. Eschwege F, Sancho-Garnier H, Chassagne D et al (1997) Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 39:275-281
78. Evans JW, Yudoh K, Delahoussaye YM et al (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58:2098-2101
79. Evans SM, Hahn S, Pook DR et al (2000) Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60:2018-2024
80. Evans JW, Chernikova SB, Kachnic LA et al (2008) Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 68:257-265
81. Everett SA, Naylor MA, Patel KB et al (1999) Bioreductively-activated prodrugs for targetting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives. Bioorg Med Chem Lett 9:1267-1272
82. Fitzsimmons SA, Lewis AD, Riley RJ et al (1994) Reduction of 3-amino-1, 2, 4-benzotriazine-1, 4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15:1503-1510
83. Foehrenbacher A, Patel K, Abbattista M et al (2013) The role of bystander effects in the anti-tumor activity of the hypoxia-activated prodrug PR-104. Front Oncol 3:263. doi:10.3389/fonc.2013.00263
84. Ghatage P, Sabagh H (2012) Is there a role for tirapazamine in the treatment of cervical cancer? Expert Opin Drug Metab Toxicol 8:1589-1597
85. Giaccia A, Siim BG, Johnson RS (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2:803-811
86. Gnarra JR, Zhou S, Merrill MJ et al (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93:10589-10594
87. Golding SE, Rosenberg E, Valerie N et al (2009) Improved ATM kinase inhibitor KU-60019 radio-sensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 8:2894-2902
88. Graeber TG, Osmanian C, Jacks T et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91
89. Graham MA, Senan S, Robin H Jr et al (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40:1-10
90. Gray LH, Conger AD, Ebert M et al (1953) Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648
91. Grigsby PW, Winter K, Wasserman TH et al (1999) Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 44:513-517
92. Gu Y, Patterson AV, Atwell GJ et al (2009) Roles of DNA repair and reductase activity in the cyto-toxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 8:1714-1723
93. Guise CP, Wang A, Thiel A et al (2007) Identification of human reductases that activate the dini-trobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74:810-820
94. Guise CP, Abbattista M, Singleton RS et al (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70:1573-1584
95. Guise CP, Abbattista MR, Tipparaju SR et al (2012) Diflavin oxidoreductases activate the biore-ductive prodrug PR-104A under hypoxia. Mol Pharmacol 81:31-40
96. Hall EJ, Roizin-Towle L (1975) Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology 117:453-457
97. Hay MP, Wilson WR, Denny WA (1999) Nitrobenzyl carbamate prodrugs of enediynes for nitrore-ductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg Med Chem Lett 9:3417-3422
98. Hay MP, Gamage SA, Kovacs MS et al (2003) Structure-activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem 46:169-182
99. Hay MP, Hicks KO, Pruijn FB et al (2007a) Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1, 2, 4-benzotriazine 1, 4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 50:6392-6404
100. Hay MP, Pchalek K, Pruijn FB et al (2007b) Hypoxia-selective 3-alkyl 1, 2, 4-benzotriazine 1, 4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem 50:6654-6664
101. Hay MP, Hicks KO, Pchalek K et al (2008) Tricyclic [1, 2, 4]triazine 1, 4-dioxides as hypoxia selective cytotoxins. J Med Chem 51:6853-6865
102. Hay MP, Turcotte S, Flanagan JU et al (2010) 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J Med Chem 53:787-797
103. Heldin CH, Rubin K, Pietras K et al (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4:806-813
104. Helleday T, Petermann E, Lundin C et al (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8:193-204
105. Hicks KO, Fleming Y, Siim BG et al (1998) Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42:641-649
106. Hicks KO, Pruijn FB, Sturman JR et al (2003) Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multi-cellular layer cultures. Cancer Res 63:5970-5977
107. Hicks KO, Siim BG, Pruijn FB et al (2004) Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat Res 161:656-666
108. Hicks KO, Pruijn FB, Secomb TW et al (2006) Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 98:1118-1128
109. Hicks KO, Myint H, Patterson AV et al (2007) Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tira-pazamine. Int J Radiat Oncol Biol Phys 69:560-571
110. Hicks KO, Siim BG, Jaiswal JK et al (2010) Pharmacokinetic/ pharmacodynamic modeling identi-fies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 16:4946-4957
111. Hickson I, Zhao Y, Richardson CJ et al (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64:9152-9159
112. Hill RP (1986) Sensitizers and radiation dose fractionation: results and interpretations. Int J Radiat Oncol Biol Phys 12:1049-1054
113. Hill RP, Gulyas S, Whitmore GF (1986) Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br J Cancer 53:743-751
114. Hill RP, Marie-Egyptienne DT, Hedley DW (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19:106-111
115. Hoogsteen IJ, Lok J, Marres HA et al (2009) Hypoxia in larynx carcinomas assessed by pimonida-zole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. Eur J Cancer 45:2906-2914
116. Horsman MR, Mortensen LS, Petersen JB et al (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9:674-687
117. Houghton PJ, Lock R, Carol H et al (2011) Initial testing of the hypoxia activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 57:443-453
118. Huang LE, Bindra RS, Glazer PM et al (2007) Hypoxia-induced genetic instability-a calculated mechanism underlying tumor progression. J Mol Med 85:139-148
119. Hunter FW, Wang J, Patel R et al (2012) Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. Biochem Pharmacol 83:574-585
120. Isaacs JS, Jung YJ, Mimnaugh EG et al (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944
121. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
122. Jameson MB, Rischin D, Pegram M et al (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791-801
123. Janssens GO, Rademakers SE, Terhaard CH et al (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30:1777-1783
124. Jenkins TC, Naylor MA, O'Neill P et al (1990) Synthesis and evaluation of alpha-[[(2-haloethyl) amino]methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl) methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensi-tizers and bioreductively activated cytotoxins. J Med Chem 33:2603-2610
125. Johnson CA, Kilpatrick D, von Roemeling R et al (1997) Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 15:773-780
126. Jones NP, Schulze A (2012) Targeting cancer metabolism-aiming at a tumor's sweet-spot. Drug Discov Today 17:232-241
127. Jubb AM, Buffa FM, Harris AL (2010) Assessment of tumor hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14:18-29
128. Kaanders JH, Bussink J, van der Kogel AJ (2002) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3:728-737
129. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689-698
130. Kaelin WG Jr (2008) The von Hippel-Lindau tumor suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8:865-873
131. Kallman RF (1972) The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 105:135-142
132. Kallman RF, Dorie MJ (1986) Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 12:681-685
133. Karasawa K, Sunamura M, Okamoto A et al (2008) Efficacy of novel hypoxic cell sensitiser dora-nidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol 87:326-330
134. Kashishian A, Douangpanya H, Clark D et al (2003) DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2:1257-1264
135. Kelson AB, McNamara JP, Pandey A et al (1998) 1, 2, 4-Benzotriazine 1, 4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anticancer Drug Des 13:575-592
136. Kioi M, Vogel H, Schultz G et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120:694-705
137. Kobori M, Shinmoto H, Tsushida T et al (1997) Phloretin-induced apoptosis in B16 melanoma 4A5 cells by inhibition of glucose transmembrane transport. Cancer Lett 119:207-212
138. Koch CJ (1993) Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53:3992-3997
139. Koch CJ, Scheuermann JS, Divgi C et al (2010) Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 37:2048-2059
140. Komar G, Seppanen M, Eskola O et al (2008) 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 49:1944-1951
141. Kovacs MS, Hocking DJ, Evans JW et al (1999) Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80:1245-1251
142. Kuiper C, Molenaar IGM, Dachs GU et al (2010) Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endome-trial cancer. Cancer Res 70:5749-5758
143. Kummar S, Raffeld M, Juwara L et al (2011) Multihistology, target-driven pilot trial of oral topo-tecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 17:5123-5131
144. Kurtoglu M, Maher JC, Lampidis TJ (2007) Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 9:1383-1390
145. Kyle AH, Minchinton AI (1999) Measurement of delivery and metabolism of tirapazamine to tumor tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43:213-220
146. Laderoute K, Wardman P, Rauth AM (1988) Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233). Biochem Pharmacol 37:1487-1495
147. Le QT, Sutphin PD, Raychaudhuri S et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67
148. Le QT, Fisher R, Oliner KS et al (2012) Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 18:1798-1807
149. Lee AE, Wilson WR (2000) Hypoxia-dependent retinal toxicity of bioreductive anticancer pro-drugs in mice. Toxicol Appl Pharmacol 163:50-59
150. Lee DJ, Cosmatos D, Marcial VA et al (1995) Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.[comment]. Int J Radiat Oncol Biol Phys 32:567-576
151. Lee N, Nehmeh S, Schoder H et al (2009) Prospective trial incorporating pre-/mid-treatment [(18) F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75:101-108
152. Lim AM, Rischin D, Fisher R et al (2012) Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res 18:301-307
153. Lin AJ, Cosby LA, Shanky CW et al (1972) Potential bioreductive alkylating agents. I. Benzoquinone derivatives. J Med Chem 15:1247-1252
154. Liu Q, Sun JD, Wang J et al (2012) TH-302, a hypoxia-activated prodrug with broad in vivo pre-clinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 69:1487-1498
155. Lo SS, Fakiris AJ, Chang EL et al (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7:44-54
156. Lohse I, Rasowski J, Cao PJ et al (2012) Targeting tumor hypoxia in patient-derived pancreatic xenografts using TH-302. In: AACR Pancreatic Cancer meeting, Lake Tahoe, 18-20 June 2012
157. Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482
158. Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662
159. Maluf FC, Leiser AL, Aghajanian C et al (2006) Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16:1165-1171
160. Mason RP, Holtzman JL (1975) The role of catalytic superoxide formation in the O2 inhibition of nitroreductase. Biochem Biophys Res Commun 67:1267-1274
161. Maxwell PH, Dachs GU, Gleadle JM et al (1997) Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104-8109
162. Mazure NM, Chen E Y, Yeh P et al (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56:3436-3440
163. McKeage MJ, Gu Y, Wilson WR et al (2011) A phase I trial of PR-104, a pre-prodrug of the bio-reductive prodrug PR-104A, given weekly to solid tumor patients. BMC Cancer 11:432
164. McKeown SR, Cowen RL, Williams KJ (2007) Bioreductive drugs: from concept to clinic. Clin Oncol 19:427-442
165. Meng F, Evans JW, Bhupathi D et al (2012) Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 11:740-751
166. Milbank JB, Stevenson RJ, Ware DC et al (2009) Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3- (5, 6, 7-trimethoxyindol-2-ylcarbonyl)-2, 3-dihydro-1, H-pyrrolo[3, 2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J Med Chem 52:6822-6834
167. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumors. Nat Rev Cancer 6:583-592
168. Minchinton AI, Lemmon MJ, Tracy M et al (1992) Second-generation 1, 2, 4-benzotriazine 1, 4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo. Int J Radiat Oncol Biol Phys 22:701-705
169. Minchinton AI, Wendt KR, Clow KA et al (1997) Multilayers of cells growing on a permeable support. An in vitro tumor model. Acta Oncol 36:13-16
170. Moeller BJ, Cao Y, Li CY et al (2004) Radiation activates HIF-1 to regulate vascular radiosensitiv-ity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429-441
171. Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 5:99-110
172. Mohindra JK, Rauth AM (1976) Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res 36:930-936
173. Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8:661-668
174. Murat A, Migliavacca E, Hussain SF et al (2009) Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One 4:e5947
175. Murata R, Tsujitani M, Horsman MR (2008) Enhanced local tumor control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol 87:331-338
176. Naylor MA, Stephens MA, Cole S et al (1990) Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33:2508-2513
177. Naylor MA, Threadgill MD, Showalter HD et al (1993) Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Des Discov 10:249-255
178. Nishimura Y, Nakagawa K, Takeda K et al (2007) Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung
179. Nordsmark M, Bentzen SM, Rudat V et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24
180. Olive PL, Vikse CM, Banath JP (1996) Use of the comet assay to identify cells sensitive to tira-pazamine in multicell spheroids and tumors in mice. Cancer Res 56:4460-4463
181. Olive PL, Banath JP, Sinnott LT (2004) Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1, 2, 4-benzotriazine-1, 3-dioxide. Cancer Res 64:5363-5369
182. Overgaard J (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509-518
183. Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066-7440
184. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 100:22-32
185. Overgaard J (2012) IAEA-HypoX. Accelerated radiotherapy with or without Nimorazole in squamous cell carcinoma of the head and neck. http:// clinicaltrialsgov/ct2/show/NCT01507467
186. Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21
187. Overgaard J, Overgaard M, Nielsen OS et al (1982) A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 46:904-911
188. Overgaard J, Overgaard M, Timothy AR (1983) Studies of the pharmacokinetic properties of nimorazole. Br J Cancer 48:27-34
189. Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135-146
190. Overgaard J, Eriksen JG, Nordsmark M et al (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764
191. Oya N, Shibamoto Y, Sasai K et al (1995) Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys 33:119-127
192. Palmer BD, Wilson WR, Cliffe S et al (1992) Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem 35:3214-3222
193. Palmer BD, Wilson WR, Atwell GJ et al (1994) Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N, N-bis(2-chloroethyl)amino]-2, 4-dinitrobenzamide. J Med Chem 37:2175-2184
194. Palmer BD, Wilson WR, Anderson RF et al (1996) Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N, N-bis(2-chloroethyl)amino]-2, 4-dinitrobenzamide. J Med Chem 39:2518-2528
195. Papadopoulou M V, Ji M, Rao MK et al (2003) Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14:21-29
196. Parker LL, Lacy SM, Farrugia LJ et al (2004) A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J Med Chem 47:5683-5689
197. Parveen I, Naughton DP, Whish WJ et al (1999) 2-nitroimidazol-5-ylmethyl as a potential biore-ductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. Bioorg Med Chem Lett 9:2031-2036
198. Patel K, Lewiston D, Gu Y et al (2007) Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 856:302-311
199. Patel K, Choy SF, Hicks KO et al (2011) A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol 67:1145-1155
200. Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as pro-drug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12:119-134
201. Patterson AV, Saunders MP, Chinje EC et al (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76:1338-1347
202. Patterson AV, Saunders MP, Chinje EC et al (1998) Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 13:541-573
203. Patterson AV, Ferry DM, Edmunds SJ et al (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 13:3922-3932
204. Patterson AV, Jaiswal J, Syddall SP et al (2009) Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia-activated irreversible pan-HER inhibitor. Mol Cancer Ther 8:Abstract B76
205. Peasland A, Wang LZ, Rowling E et al (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 105:372-381
206. Phillips RM, Hendriks HR, Peters GJ (2013) EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol 168:11-18
207. Pires IM, Olcina MM, Anbalagan S et al (2012) Targeting radiation-resistant hypoxic tumor cells through ATR inhibition. Br J Cancer 107:291-299
208. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 11:e26
209. Pries AR, Cornelissen AJ, Sloot AA et al (2009) Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 5:e1000394
210. Pruijn FB, Sturman JR, Liyanage HDS et al (2005) Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogs in multicellular layer cultures. J Med Chem 48:1079-1087
211. Pruijn FB, Patel K, Hay MP et al (2008) Prediction of tumor tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters. Aust J Chem 61:687-693
212. Raleigh JA, Calkins-Adams DP, Rinker LH et al (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58:3765-3768
213. Ramanathan RK, Kirkpatrick DL, Belani CP et al (2007) A Phase I pharmacokinetic and pharma-codynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13:2109-2114
214. Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316-4324
215. Rapisarda A, Uranchimeg B, Sordet O et al (2004a) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475-1482
216. Rapisarda A, Zalek J, Hollingshead M et al (2004b) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845-6848
217. Rapisarda A, Hollingshead M, Uranchimeg B et al (2009) Increased antitumor activity of bevaci-zumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8:1867-1877
218. Reaper PM, Griffiths MR, Long JM et al (2011) Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7:428-430
219. Reddy SB, Williamson SK (2009) Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18:77-87
220. Ren H, Accili D, Duan C (2010) Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. Proc Natl Acad Sci USA 107:5857-5862
221. Rini BI (2010) New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16:1348-1354
222. Rischin D, Peters L, Fisher R et al (2005) Tirapazamine, cisplatin, and radiation versus fluoroura-cil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79-87
223. Rischin D, Hicks RJ, Fisher R et al (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104
224. Rischin D, Narayan K, Oza AM et al (2010a) Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. Int J Gynecol Cancer 20:827-833
225. Rischin D, Peters LJ, O'Sullivan B et al (2010b) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995
226. Rockwell S, Dobrucki IT, Kim EY et al (2009) Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9:442-458
227. Salas-Burgos A, Iserovich P, Zuniga F et al (2004) Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 87:2990-2999
228. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
229. Sapra P, Zhao H, Mehlig M et al (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888-1896
230. Sapra P, Kraft P, Pastorino F et al (2011) Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14:245-253
231. Sarkaria JN, Eshleman JS (2001) ATM as a target for novel radiosensitizers. Semin Radiat Oncol 11:316-327
232. Saunders M, Dische S (1996) Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 27:S271-S278
233. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732
234. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12:853-859
235. Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51-56
236. Senan S, Rampling R, Graham MA et al (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31-38
237. Senra JM, Telfer BA, Cherry KE et al (2011) Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10:1949-1958
238. Shepherd F, Koschel G, von Pawel J et al (2000) Comparison of Tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): final results of the international phase III CATAPULT II trial. Lung Cancer 29(Suppl 1):28, abstract No. 87
239. Shewach DS, Lawrence TS (2007) Antimetabolite radiosensitizers. J Clin Oncol 25:4043-4050
240. Shinde SS, Hay MP, Patterson AV et al (2009) Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J Am Chem Soc 131:14220-14221
241. Shinde SS, Maroz A, Hay MP et al (2010) Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (tirapazamine). J Am Chem Soc 132:2591-2599
242. Shinohara ET, Geng L, Tan J et al (2005) DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65:4987-4992
243. Siim BG, van Zijl PL, Brown JM (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumor cells in vitro. Br J Cancer 73:952-960
244. Singleton RS, Guise CP, Ferry DM et al (2009) DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res 69:3884-3891
245. Song CW, Clement JJ, Levitt SH (1976) Preferential cytotoxicity of 5-thio-D-glucose against hypoxic tumor cells. J Natl Cancer Inst 57:603-605
246. Sun JD, Liu Q, Wang J et al (2012) Selective tumor hypoxia targeting by hypoxia-activated pro-drug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 18:758-770
247. Sutphin PD, Chan DA, Li JM et al (2007) Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 67:5896-5905
248. Sutphin PD, Chan D, Turcotte S et al (2011) Heteroaryl benzamides, compositions and methods of use. Patent WO2011011514 A1
249. Tatsumi K, Kitamura S, Narai N (1986) Reductive metabolism of aromatic nitro compounds including carcinogens by rabbit liver preparations. Cancer Res 46:1089-1093
250. Tatum JL, Kelloff GJ, Gillies RJ et al (2006) Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82:699-757
251. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and possible implications for radiotherapy. Br J Cancer 9:539-549
252. Threadgill MD, Webb P, O'Neill P et al (1991) Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins. J Med Chem 34:2112-2120
253. Timothy AR, Overgaard J, Overgaard M (1984) A phase I clinical study of Nimorazole as a hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 10:1765-1768
254. Toustrup K, Sorensen BS, Nordsmark M et al (2011) Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 71:5923-5931
255. Toustrup K, Sorensen BS, Alsner J et al (2012) Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 22:119-127
256. Turcotte S, Chan DA, Sutphin PD et al (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14:90-102
257. Tuttle SW, Maity A, Oprysko PR et al (2007) Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration. J Biol Chem 282:36790-36796
258. Ueda O, Kitamura S, Ohashi K et al (2003) Xanthine oxidase-catalysed metabolism of 2-nitrofluorene, a carcinogenic air pollutant, in rat skin. Drug Metab Dispos 31:367-372
259. Urtasun RC, Band P, Chapman JD et al (1976) Radiation and high dose metronidazole in supraten-torial glioblastomas. N Engl J Med 294:1364-1367
260. van Loon J, Janssen MHM, Ollers M et al (2010) PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 37:1663-1668
261. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239
262. Vaupel P, Hockel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9:1221-1235
263. von Pawel J, von Roemeling R, Gatzemeier U et al (2000) Tirapazamine plus cisplatin versus cis-platin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18:1351-1359
264. Wang H, Wang H, Powell SN et al (2004) ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining. Cancer Res 64:7139-7143
265. Wang D, Chu PC, Yang CN et al (2012a) Development of a novel class of glucose transporter inhibitors. J Med Chem 55:3827-3836
266. Wang J, Foehrenbacher A, Su J et al (2012b) The 2-nitroimidazole EF5 is a biomarker for oxido-reductases that activate bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res 18:1684-1695
267. Wardman P (2001) Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8:739-761
268. Wardman P (2007) Chemical radiosensitizers for use in radiotherapy. Clin Oncol 19:397-417
269. Ware DC, Palmer BD, Wilson WR et al (1993) Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem 36:1839-1846
270. Welsh SJ, Williams RR, Birmingham A et al (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endo-thelial growth factor formation. Mol Cancer Ther 2:235-243
271. Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
272. Williams KJ, Telfer BA, Xenaki D et al (2005) Enhanced response to radiotherapy in tumors defi-cient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89-98
273. Williamson SK, Crowley JJ, Lara PN Jr et al (2005) Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23:9097-9104
274. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410
275. Wilson WR, van Zijl P, Denny WA (1992) Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int J Radiat Oncol Biol Phys 22:693-696
276. Wilson WR, Hicks KO, Pullen SM et al (2007) Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 167:625-636
277. Winter SC, Buffa FM, Silva P et al (2007) Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67:3441-3449
278. Wood TE, Dalili S, Simpson CD et al (2008) A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 7:3546-3555
279. Wouters BG, Brown JM (1997) Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147:541-550
280. Xia Y, Choi HK, Lee K (2012) Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49:24-40
281. Yamamoto N, Renfrew AK, Kim BJ et al (2012) Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex. J Med Chem 55:11013-11021
282. Yin J, Glaser R, Gates KS (2012) On the reaction mechanism of tirapazamine reduction chemistry: unimolecular N-OH homolysis, stepwise dehydration, or triazene ring-opening. Chem Res Toxicol 25:634-645
283. Zeman EM, Brown JM, Lemmon MJ et al (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242
284. Zeman EM, Hirst VK, Lemmon MJ et al (1988) Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12:209-218
285. Zeman EM, Baker MA, Lemmon MJ et al (1989) Structure-activity relationships for benzotriazine di-N-oxides. Int J Radiat Oncol Biol Phys 16:977-981
286. Zhao Y, Thomas HD, Batey MA et al (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66:5354-5362
287. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545